News

Latest News

View All

Adair Newhall of Greenspring Associates Interview Doug Ward, CEO of PGDx

Doug Ward is Chief Executive Officer of Personal Genome Diagnostics (PGDx), a Baltimore company empowering the fight against cancer by unlocking actionable information from the human genome. He has more than 25 years of experience within the diagnostic market, including leadership positions at top-tier molecular diagnostics and testing innovators such as Roche, GE Healthcare, Siemens…

PGDx to Develop Liquid Biopsy Companion Dx for Five Prime Therapeutics’ Drug Candidate

NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that it has entered a collaboration with Five Prime Therapeutics to develop a blood-based companion diagnostic assay for use with Five Prime’s investigational drug candidate, bemarituzumab.Under the agreement, PGDx is creating and validating a circulating tumor DNA test to identify the approximately 10…

PGDx signs licensing deal with Memorial Sloan Kettering Cancer Center

Personal Genome Diagnostics is adding to its IP portfolio to further develop new kinds of cancer tests.A licensing deal announced Wednesday gives the Canton-based company exclusive rights to develop and commercialize products based on a key discovery at Memorial Sloan Kettering Cancer Center in New York. Financial terms were not disclosed.The two entities were both…